Binghe H. Xu

Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100006, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 369 publications

A predictive model of survival in early-stage medullary breast carcinoma: a population-based study.

A predictive model of survival in early-stage medullary breast carcinoma: a population-based study.

Journal: Hong Kong medical journal = Xianggang yi xue za zhi
Published: August 12, 2026

Interpretation of the BRIGHT-2 Trial-Reply.

Interpretation of the BRIGHT-2 Trial-Reply.

Journal: JAMA oncology
Published: July 30, 2026

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA oncology
Published: June 01, 2026

Turmoil and breakthroughs: Highlights and growing pains in breast cancer therapy 2025-2026.

Turmoil and breakthroughs: Highlights and growing pains in breast cancer therapy 2025-2026.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: May 01, 2026

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

Journal: Thoracic cancer
Published: April 12, 2026

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology
Published: March 19, 2026

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.

Journal: ESMO open
Published: March 02, 2026

Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway.

Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway.

Journal: Cancer letters
Published: January 14, 2026

Standard: human breast cancer organoids derived from diverse clinical sample sources.

Standard: human breast cancer organoids derived from diverse clinical sample sources.

Journal: Cell regeneration (London, England)
Published: January 02, 2026

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition).

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition).

Journal: Cancer innovation
Published: December 22, 2025

Multicellular force coordination constructs microchannel networks for barrier-free metastasis across extracellular matrix.

Multicellular force coordination constructs microchannel networks for barrier-free metastasis across extracellular matrix.

Journal: Science advances
Published: December 19, 2025

Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer.

Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: December 10, 2025
Showing 1-12 of 369

Last Updated: 09/26/2026